Redx Pharma plc
Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class
Mr Nicholas AdamsCBO
Riemser Pharma GmbH
RIEMSER Pharma GmbH is a European specialty pharmaceutical company established in December 1992 with core competencies focused niche therapy areas with high unmet medical need.
RIEMSER markets its own product portfolio in numerous therapeutic areas including oncology, neurology, anti-infectives and dermatology.
RIEMSER is present with own affiliates in Germany, France and UK and is selling its products in > 60 countries worldwide through a network of trusted partners.
We are looking to strengthen our portfolio through licensing or acquisition.